Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Phase III STRENGTH trial for Epanova in mixed dyslipidaemia will close
On recommendations by an independent committee, AstraZeneca will close its STRENGTH trial for Epanova, which has shown low likelihood of being beneficial to patients with mixed dyslipidaemia.
Governor of California proposes state-run drug label
In a bid to lower the costs of medicines, California’s governor has suggested contracting generic drug manufacturers to make pharmaceutical products for the state to sell, according to reports.
China pneumonia outbreak not spreading at present: WHO
LONDON/BEIJING (Reuters) - An outbreak of pneumonia that has killed one person in China and infected 40 others appears to be linked to a single seafood market in the central city of Wuhan and ...
Eli Lilly to launch half-priced versions of two more insulin products
(Reuters) - Eli Lilly and Co said on Tuesday it plans to sell two versions of insulin products at half their current U.
Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer
(Reuters) - Biogen Inc said on Monday it has agreed to buy an early-stage experimental treatment from Pfizer Inc that it aims to test in patients with Alzheimer’s and Parkinson’s disease.
Chinese hospital cures patients with 3D-printed implants
BEIJING, Jan.
Lilly Announces Agreement to Acquire Dermira
INDIANAPOLIS and MENLO PARK, Calif.
AI specialist Exscientia signs drug discovery tie-up with Bayer
UK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking to use its platform to find new cardiovascular and cancer drugs.
Celgene backs out of $55M class action settlement on claims it blocked copycats to Revlimid, Thalomid
In an unusual move, Celgene has backed out of a $55 million settlement with patients and payers over allegations it illegally blocked competition to multiple myeloma meds Thalomid and Revlimid.
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
Today, the U.
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE.
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1
Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and its skin cancer and alopecia drug BNZ-1.
354
355
356
357
358
359
360
361
362
